Congrats to Prof Trevor Leong and TOPGEAR trial investigators on publication of significant findings at #ESMO24 and in NEJM this weekend. We're thrilled to have collaborated on this important trial with GI Cancer Institute and AGITG and others.

☢️Neoadjuvant CRT vs. ChT for initially unresectable locally advanced "Colon" cancer eClinicalMedicine – The Lancet Discovery Science ➡️45 patients ✅R0 resection: 80% vs. 20%, P < 0.001 ✅3-year PFS: 76% vs. 45% , P = 0.049 ✅3-year OS: 87.6% vs. 75% , P = 0.037 ✅No differences in severe AEs ❗️Study was

In this study of patients receiving combined locoregional and immunotherapies (LRT-IO) for unresectable HCC, 46% had complete response (CR) and 75% remained alive at 3 years. Watch and wait was shown feasible in CR patients after LRT-IO. ja.ma/4dlkbkH

Another setting where SBRT underutilized IMO in HCC is bridge to transplant. I am convinced w modern tech, SBRT can safely prevent local progression in most. Study shows similar transplant outcomes post SBRT/TACE/RFA, despite SBRT pts w worse liver fxn journal-of-hepatology.eu/article/S0168-…

Just in time for #CTOS2024: Thrilled to share SU2C-SARC032 (NCT03092323), a randomized trial of pembrolizumab in Stage 3 extremity soft tissue sarcoma, now published The Lancet! authors.elsevier.com/a/1k5JbV-4XOupH 1/13 SARC Stand Up To Cancer CTOS Radiation Medicine Program Princess Margaret Cancer Centre University Health Network Radiation Oncology

M. Bolton Fantastic! Here is the HR for SBRT vs. TACE in our work. EBRT was associated with improved PFS over TACE (HR: 0.37, 95% CI = 0.23-0.60; I2 = 0%). Here is the abstract from #ASTRO24, the full publication was just accepted in Cancer today! redjournal.org/article/S0360-…

RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer. N=135 w unresectable GBC, after 4c chemo, addition of RT (vs. obs) improved OS from 4 to 10 months. Several limitations (single center, chemo gem/cis & 4 mo) but OS benefit shouldn’t be ignored.

🚨 🚨 RCT of SBRT vs RFA for recurrent small HCC HR for local progression free survival a whopping 0.45 (0.95 CI 0.24-0.87) with SBRT vs RFA More data of the inferiority of IR ablation for HCC ascopubs.org/doi/10.1200/JC…

Proud to see RTOG1112 RCT published!. Thanks to so many who helped make this possible. #teamwork ‘Hope the next #SBRT #HCC trials are completed much faster. NRG Oncology Ted Hong Ali Hosni Arndt Vogel Aisling Barry Nice summary of the trial below from Dr. Nina Niu Sanford

External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial - International Journal of Radiation Oncology, Biology, Phys redjournal.org/article/S0360-…

❗️ RCT of proton RT vs TACE in HCC mPFS for PBT vs TACE was not reached vs. 12 months, p = .002; with a whopping HR 3.62 (1.62–8.05) TACE is a very poor treatment 👎

🚨ESOPEC Pub has landed!🚨 See data review below! For now, "standard" will appropriately shift to peri-operative FLOT BUT we should not be satisfied as outcomes remain suboptimal Ongoing ❓❓ - does TNT (FLOT + CRT) offer further benefit? - is it time to consider organ

🚨SCIENCE Ph3 RCT🚨 🔥Check this one out🔥 cT2-4N0-3, T1N2-3 Eso SCC 1️⃣neo Carbo + nabPaclitaxel + Sintilimab 2️⃣nCRT 41.4/23) wCarbo-taxol + Sintilimab 3️⃣nCRT ✅⬆️⬆️pCR CRT vs chemo (13% with chemo) ✅Sintilimab + CRT vs CRT ⬆️ pCR (60% v 47%) without added AEs #GI25 ASCO

Sharing our work from Peter Mac Radiation Oncology published Clinical Oncology, reporting that neoadjuvant CRT can be clinically useful for highly selected colon cancers. Our results support the Zhang ph 3 study which showed efficacy of CRT for unresectable colon cancers. clinicaloncologyonline.net/article/S0936-…

Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial) 💥OS after active surveillance was not inferior to standard surgery at 2 years thelancet.com/journals/lanon…

First of 2 consensus statements coming out for #NPC. This one is an effort undertaken with most of the participants from #LMIC settings. Excellent inclusivity effort from Warren Bacorro and team. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

It’s out!!! 🔥🔥🔥 The PREOPANC-2 is in The Lancet Oncology Neoadjuvant FOLFIRINOX 🤜🤛 Gemcitabine based chemoradiotherapy in resecatble / BR ⚖️ No difference in overall survival 😰 Serious adverse events 40% 👍 Both regimens may be considered thelancet.com/journals/lanon…

🔬 Critical Evaluation of TNT in LARC 🔗 doi.org/10.1200/OP-25-… 🧬 Review of RAPIDO, PRODIGE-23, POLISH II & STELLAR 💊 Small DFS gain · OS benefit uncertain · Added toxicity 📊 CRT remains standard; biomarkers needed for selection #DraMartinezLago #GItumors

🧠 You can shrink the tumour—but not the tumour bed. New RAPIDO analysis in BJS 2025 shows why small margins after TNT can turn dangerous 👇 💡 Trial: RAPIDO (n = 920, LARC) 🎯 TNT = 5×5 Gy + 6 CAPOX / 9 FOLFOX → TME vs CRT = 25–28×1.8–2 Gy + capecitabine → TME 📊 8-year

The kiss 💋 between nab-paclitaxel / gem and FOLFINIRNOX ?! ♥️ Neoadjuvant regimens combined in resectable 💉 RCT 324 pts vs. Upfront surgery median EFS 15 vs. 10 months? 🧐 Doubts about control group, but again in the direction of neoadjuvant to all! cell.com/action/showPdf…